Cell Therapy News/Articles, page-10342

You are wrong Sorepocket.

The company has said when asked, the Novtis deal is signed. The have a signed legal contract that is awaiting on closing conditions, one of which is time for Novartis to examine the data. We don't know what the other conditions are - they may well be that Novartis must create potency assays that are accepted by the FDA. You are speculating that MSB have entered into a purely 1 sided deal where Novartis have no conditions they have to meet, which you have no proof of. It's "probably" very unrealistic, given MSB already said they wanted to use Novartis expertise in some areas, that they would not include that in the contract somewhere.

No use really giving any % chance of the closing conditions. We all know the data is good, it will be some other non-disclosed closing condition that might stop the deal in my opinion, and nobody has any clue what they are or who ( MSB or Novartis ) is responsible for them.
We should all find out soon enough though.

What is clear is that both Novartis and MSB have no "choice" apart from to follow the closing conditions of the signed legal contract. If the deal was based on the data alone, I think deal would have completed months ago... as soon as the 60 day information was released. Clearly, there is another closing condition holding it up.